Sweden

Alligator Bioscience

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SWEDEN Sweden

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Alligator Bioscience AB (publ) Interim Report January-June 2020

Lead Product(s): ATOR-1015

Therapeutic Area: Oncology Product Name: ATOR-1015

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable July 13, 2020

Details:

Interim data from up to 21 cancer patients was presented at the oncology conferences AACR and ASCO, showing a promising safety and tolerability for ATOR-1015. Currently, patients are given doses of 750 mg, approximately 12.5 mg/kg, every two weeks.

Alligator Bioscience

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SWEDEN Sweden

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Alligator Bioscience Receives First Patent Approval for ATOR-1017

Lead Product(s): ATOR-1017

Therapeutic Area: Oncology Product Name: ATOR-1017

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 23, 2020

Details:

US Patent Office (USPTO) has issued an approved patent for the drug candidate ATOR-1017, Alligator's wholly owned 4-1BB antibody in clinical development phase I for the treatment of disseminated cancer.

Oasmia Pharmaceutical

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SWEDEN Sweden

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Oasmia Pharmaceutical AB Signs Phase 1b Trial Agreement with SAKK

Lead Product(s): Docetaxel

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: SAKK

Deal Size: Undisclosed Upfront Cash: Undisclosed

Deal Type: Agreement June 08, 2020

Details:

SAKK is the legal sponsor of the project and responsible to conduct the phase 1B trial. Oasmia’s main role in the project is to supply its formulation of docetaxel and carry the cost of the trial, which are deemed not material to Oasmia.

Active Biotech

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SWEDEN Sweden

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Active Biotech Provides Status Update in the Portfolio Projects

Lead Product(s): Naptumomab estafenatox,Durvalumab

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable June 03, 2020

Details:

The Phase 1b/2 study with naptumomab in combination with the checkpoint inhibitor durvalumab in patients with advanced solid tumors aims to establish the maximum tolerated dose of the combination before advancing to a larger cohort expansion phase in the United States.

Alligator Bioscience

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SWEDEN Sweden

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Alligator Bioscience Presents Novel Supportive Phase I Data at ASCO for its CTLA-4 x OX40 Bispecific Drug Candidate ATOR-1015

Lead Product(s): ATOR-1015

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 29, 2020

Details:

The results of the evaluation of doses up to and including 600 mg (about 10 mg / kg) show that ATOR-1015 is well tolerated and the dose scaling has progressed to 750 mg (12.5 mg / kg).

Cantargia AB

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SWEDEN Sweden

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Cantargia IND Application for CAN04 Approved by FDA

Lead Product(s): Nidanilimab,Pembrolizumab

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable May 04, 2020

Details:

CAN04, an antibody targeting IL1RAP, is currently being investigated for treatment of non-small cell lung cancer (NSCLC) and pancreatic cancer (PDAC) in phase IIa clinical development.

Alligator Bioscience

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SWEDEN Sweden

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Alligator Bioscience Increases Focus on Clinical Development

Lead Product(s): ATOR-1015

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Large molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 07, 2020

Details:

Study OC5-DB-02 (ePHex) is a 12-month randomized Phase 3 study to evaluate the efficacy and safety of Oxabact OC5 in adults and children with primary hyperoxaluria (PH) of all types.

Lidds

Upgrade this company profile, update & customize all content// Ask PharmaCompass, click HERE

SWEDEN Sweden

Post An Enquiry

Virtual Booth

CAMBODIA PHAR-MED 2020

Participation Not Confirmed

Update your events

Additional patients treated in LIDDS clinical study NZ-DTX-001

Lead Product(s): Docetaxel

Therapeutic Area: Oncology Product Name: Undisclosed

Highest Development Status: Phase I Product Type: Small molecule

Partner/Sponsor/Collaborator: Not Applicable

Deal Size: Not Applicable Upfront Cash: Not Applicable

Deal Type: Not Applicable April 01, 2020

Details:

Dose escalation in the Phase I study NZ-DTX is proceeding according to the protocol, with additional patients being treated at a higher dose level of NZ-DTX.

Find

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Product Type

Companies

Alligator Bioscience

Alligator Bioscience AB (publ) Interim Report January-June 2020

Alligator Bioscience

Alligator Bioscience Receives First Patent Approval for ATOR-1017

Oasmia Pharmaceutical

Oasmia Pharmaceutical AB Signs Phase 1b Trial Agreement with SAKK

Active Biotech

Active Biotech Provides Status Update in the Portfolio Projects

Alligator Bioscience

Alligator Bioscience Presents Novel Supportive Phase I Data at ASCO for its CTLA-4 x OX40 Bispecific Drug Candidate ATOR-1015

Cantargia AB

Cantargia IND Application for CAN04 Approved by FDA

Alligator Bioscience

Alligator Bioscience Increases Focus on Clinical Development

Lidds

Additional patients treated in LIDDS clinical study NZ-DTX-001